{"id":"W3202383065","doi":"10.1016/j.annonc.2021.08.065","title":"669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Merck Sharp and Dohme; Genentech; Servier; Society for Immunotherapy of Cancer; Shionogi; Astellas Pharma; Eisai; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Exelixis; MEI Pharma; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; PTC Therapeutics; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; EUSA Pharma; AstraZeneca; American Society of Clinical Oncology; Arrowhead Pharmaceuticals; Merck; Amgen","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075423,0.001026368,0.002203218,0.0002756108,0.0004681739,0.001318213,0.0006560726,0.001031213,0.005335436],"category_scores_gemma":[0.0006697439,0.0004529316,0.001855475,0.0004110987,0.0005330474,0.001073165,0.0004013022,0.003896327,0.001398735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008315936,"about_ca_system_score_gemma":0.001062377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0012922,"about_ca_topic_score_gemma":0.004511122,"domain_scores_codex":[0.9996247,0.0001329425,0.00001640571,0.00007307309,0.0000376883,0.0001151298],"domain_scores_gemma":[0.9996367,0.00005416544,0.00007598395,0.0000313569,0.00002148961,0.0001802832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8497707,0.01720286,0.007822409,0.001450983,0.003793864,0.0002512898,0.0001587614,0.0028586,0.01308421,0.0004648822,0.006740563,0.09640086],"study_design_scores_gemma":[0.5515627,0.3822007,0.04399975,0.0002006076,0.003556537,0.0005036544,0.0001663848,0.001476094,0.003994651,0.0008102737,0.01145989,0.00006879524],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880289,0.004043723,0.0003151066,0.0004478508,0.0003048019,0.0006755181,0.001795359,0.00008032969,0.004308388],"genre_scores_gemma":[0.9869135,0.003114801,0.0005227422,0.0008066587,0.0001794118,0.0005516795,0.002722419,0.00003287887,0.005155951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005335436,"threshold_uncertainty_score":0.01784885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2049264159470167,"score_gpt":0.4405689404238316,"score_spread":0.2356425244768149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}